To further evaluate the possibility of using pharmacological inhibition of wt-IDH2 as a new treatment for AML in vivo, we tested the therapeutic efficacy of compound AGI-6780 in mice bearing subcutaneous xenografts of AML (ML-1, wt-IDH2). This evidence concerns the gene IDH2 and acute myeloid leukemia.